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7.4, p = 0.0065) among groups Vioxx, Cox2-Vioxx and Others
in the adverse events rates of 5.84%, 5.00% and 3.83% respec-
tively. Further Logistic regression anlaysis revealed that Vioxx
and Cox2-Vioxx patients experienced higher events rates (group
Vioxx vs. Others: OR = 1.218, 95%CI = 0.905–1.640; group
Cox2-Vioxx vs. Others OR = 1.13, 95%CI = 0.834–1.532) with
inﬂuencing factors adjusted, gender (male OR = 1.555, 95%CI
= 1.190–2.031), age (OR = 1.080, 95%CI = 1.063–1.097) and
comorbidities. CONCLUSIONS: The study demonstrated that
Vioxx before withdrawn from market had highest heart
attack/stroke events as compared to other Cox2 drugs or drug
class. The other Cox2 drugs, Celebrex and Bextra, had higher
adverse events than other painkiller classes such as NSAIDs. The
follow up study with extended data is expected to conﬁrm the
ﬁnding.
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OBJECTIVES: Rituximab (RTX; MabThera), a unique B-cell
therapy, is a new option for rheumatoid arthritis (RA) patients
who respond inadequately to anti-TNF therapies. This analysis
evaluated the cost-effectiveness of introducing RTX from the
perspective of the UK NHS. METHODS: The model simulated,
over a patient’s expected lifetime, the real-life treatment sequence
for 10,000 RA patients who respond inadequately to one anti-
TNF therapy. Baseline characteristics were aligned with the
REFLEX study. Clinical outcomes were based upon ACR
response rates (adjusted for different study populations) and
complemented with observational data. The model estimated the
incremental cost per quality-adjusted life-year (QALY) of a typi-
cal treatment sequence containing RTX compared to the same
treatment sequence without RTX. Average time-on-treatment for
biological agents was up to 4.25 years. QALYs were mapped
from a disease severity measure (HAQ score). All direct NHS
costs were included in the model, as well as those related to
disease progression and palliative care. Costs and beneﬁts were
discounted at 3.5%. RESULTS: The annual average drug cost
for each drug in the model was BRP5834 for RTX + MTX (infu-
sion of 2 ¥ 1 gram every 9 months), BRP10,138 for adalimumab,
BRP10,279 for etanercept, and BRP8542 for inﬂiximab. The
model estimated that when added to an existing treatment
sequence, RTX would lead to a gain of 0.526 QALYs at an ad-
ditional cost of BRP7417 per patient. The incremental cost-
effectiveness ratio (ICER) of RTX was consequently BRP14,122.
When RTX replaced adalimumab as a second-line biologic
DMARD, RTX + MTX was associated with a cost-saving of
BRP13,000 over a patient’s lifetime. CONCLUSIONS: RTX as
a treatment option for RA patients who fail to respond to anti-
TNF therapy is a cost effective treatment option from the per-
spective of the UK NHS. The resulting cost effectiveness ratio
falls well below commonly accepted thresholds within the UK.
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OBJECTIVES: Rituximab (RTX; MabThera), a unique selective
B-cell therapy, represents a new option for patients with rheuma-
toid arthritis (RA) who have responded inadequately to anti-
TNF therapies. We analysed the cost-effectiveness of RTX from
a German societal perspective. METHODS: We developed a
model using published ACR response rates for RTX and current
treatment choices (adjusted for study population differences),
plus available observational data, German registry resource-
utilisation data and baseline patient characteristics from the
REFLEX study. We modelled real-life treatment for 10,000 RA
patients who had responded inadequately to one anti-TNF
therapy over the patient’s lifetime, assuming an average treat-
ment duration for biological therapy (in combination with
methotrexate) of up to 4.25 years. QALYs were mapped from a
disease severity measure (HAQ score). Relevant costs (2004–5
Euros [€]) included those related to drug (including administra-
tion and monitoring) and indirect costs through reduced pro-
ductivity. Costs and beneﬁts were discounted at 3.5% per year.
We assessed either adding RTX or using it instead of adali-
mumab. RESULTS: Annual average drug therapy costs were
€10,208 for RTX + MTX, €22,574 for adalimumab, €22,630 for
etanercept, and €13,484 for inﬂiximab. RTX as an additional
treatment gave an additional 0.531 QALYs at an incremental
total direct medical cost of €16,527 over the patient’s lifetime.
With an incremental QALY of 0.665 this would result in an
incremental direct medical cost of €24,844 per QALY. The cor-
responding ICERs were €25,985 and €17,058 per QALY gained.
Using RTX as an alternative to adalimumab would produce a
small incremental QALY gain, together with lifetime cost-savings
of €23,143. CONCLUSIONS: In Germany, the incremental cost
of adding RTX to options for RA-patients who respond inade-
quately to anti-TNF therapy is favourable using commonly
accepted cost-effectiveness thresholds. As a replacement for a
currently used drug in second-line biologic DMARD, RTX could
lower average annual treatment costs.
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OBJECTIVES: To explore inﬂuences of patient and clinical char-
acteristics on the cost-effectiveness of selective COX-2 inhibitors
and traditional NSAIDs in patients with osteoarthritis.
METHODS: A published cost-effectiveness model (Arthritis
Rheum 2003;49:283–92) was modiﬁed to incorporate important
clinical characteristics that can inﬂuence the risk of gastroin-
testinal (GI) complications such as age, gender, history of GI
bleed, and low-dose aspirin intake. The modiﬁed model used
data from a large clinical trial (TARGET) to estimate base GI
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event rates. Differences between NSAIDs were modeled from
observed rates of GI events and adverse effects after adjusting
for differences in population characteristics across three clinical
trials (TARGET, CLASS and VIGOR). Other enhancements
included modeling: 1) serious hepatic, renal, and skin adverse
events (AEs); 2) proton pump inhibitor use after dyspepsia, while
taking an NSAID; and 3) multiple occurrences of myocardial
infarction (MI) (as opposed to one per patient). Health state util-
ities for AEs were assigned a value equal to that for the hospi-
talized surgical management of a complicated GI event. For MI,
a 5% discount factor was used to reduce the patient’s utility
score. Patients switching to acetaminophen because of an AE can
experience reduced analgesic effect compared with NSAIDs;
therefore utilities were discounted by 20%. RESULTS: The 
modiﬁed model produced lower estimates of LYs and QALYs
(approximately 0.05 and 0.08 less, respectively) compared with
the original model which could be clinically meaningful in a 
5-year model. Patient and clinical characteristics that deﬁned 
low GI-risk subgroup versus high GI-risk group produced 
differences in LYs and QALYs of up to 1 LY and 0.7 QALY.
CONCLUSION: Effectiveness can vary considerably across
patients with varying clinical characteristics. Therefore, the cost-
effectiveness of treatment in any population should consider the
heterogeneity of patients. This model provides ﬂexible means to
compare cost-effectiveness of treatment for patients with
osteoarthritis.
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OBJECTIVES: Rituximab (RTX), a unique selective B-cell
therapy, is a new option for rheumatoid arthritis (RA) patients
who respond inadequately to anti-TNF therapies. This study
reports a cost-effectiveness analysis modelling the introduction
of RTX in Italy. METHODS: We used ACR response rates
(adjusted for differences in study populations), plus observa-
tional data from EU registries and simulated real-life treatment
for 10,000 RA patients who had responded inadequately to anti-
TNF therapy, using baseline patient characteristics from the
REFLEX study. We assumed an average treatment duration for
biological therapy (in combination with methotrexate) of up to
4.25 years over the patient’s remaining lifetime. QALYs were
mapped from a disease-severity measure (HAQ score) and based
on registry data. Relevant costs included (2004–5 Euros [€]) drug
costs (including administration and monitoring) and those
related to reduced productivity (indirect costs). We assessed RTX
as either a new treatment step or instead of adalimumab.
RESULTS: Average annual treatment costs were €8796 for RTX
+ MTX, €14,133 for adalimumab, €14,406 for etanercept, and
€9950 for inﬂiximab. Compared with the current treatment
sequence, RTX + MTX as a new treatment step produced a gain
of 0.677 QALYs at an incremental total medical cost of €12,355
over the lifetime of each patient—an incremental cost-effective-
ness ratio (ICER) of €18,259 per QALY gained. The incremen-
tal cost per QALY for drug therapy or total (direct + indirect)
cost was €19,241 and €13,621. RTX used instead of adali-
mumab produced a similar QALY gain, but resulted in a total
direct medical-cost saving of €11,389 over the patient’s lifetime.
CONCLUSIONS: RTX offers a highly acceptable incremental
cost per QALY gained for Italian patients with RA who respond
inadequately to anti-TNF therapy and the possibility of either
treating more patients within an existing budget or reducing the
overall treatment cost for RA patients.
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Rituximab (RTX), is a new and unique selective B-cell therapy
for rheumatoid arthritis (RA) patients who respond inadequately
to anti-TNF therapies. OBJECTIVES: We determined the cost-
effectiveness of introducing RTX in Spain. METHODS: Our
cost-effectiveness model simulates a real-life Spanish treatment
sequence for 10,000 RA patients who had responded inade-
quately to one anti-TNF therapy. We used ACR response rates
for RTX and current treatment options, available epidemiologi-
cal data from observational studies and baseline characteristics
from the REFLEX study. The model estimated the incremental
cost per QALY gained, with RTX as either a new or alternative
treatment over each patient’s remaining lifetime, assuming 
time-on-treatment for biological agents (in combination with
methotrexate) of up to 4.25 years. QALYs came from a disease
severity measure (HAQ score). Costs included (2004–5 EURO)
drug costs (including administration and monitoring) and costs
related to disease progression, palliative care, and reduced pro-
ductivity (indirect costs). Costs and beneﬁts were discounted at
3.5% per annum. RESULTS: Annual average treatment costs
were €7431 for RTX + MTX, €14,072 for adalimumab, €13,067
for etanercept, and €9823 for inﬂiximab. Added to existing ther-
apies, RTX would lead to a gain of 0.632 QALYs at an addi-
tional total direct medical cost of €11,550 over each patient’s
lifetime. The corresponding incremental cost-effectiveness ratio
(ICER) of RTX was €18,261 per QALY gained. Corresponding
ICERs for drug therapy and total costs were €19,597 and
€15,546 per QALY gained, respectively. Used in place of etaner-
cept as second-line biologic DMARD, RTX + MTX were 
associated with lifetime drug cost-savings of over €17,000.
CONCLUSIONS: Adding RTX to the pool of available treat-
ment options for Spanish patients with RA who respond 
inadequately to anti-TNF therapy results in a favourable 
incremental cost per QALY gained. When RTX is replacing
another biologic DMARD, the average annual drug therapy
costs can be lowered.
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OBJECTIVES: Nonsteroidal antiinﬂammatory drugs (NSAIDs)
are in widespread use for rheumatic diseases in Mexico, but can
cause peptic ulcers and gastrointestinal bleeding and perforation.
The purpose of this study was to evaluate cost—effectiveness
ratios of celecoxib compared with NSAIDs and acetaminophen
in adult patients with osteoarthritis in four hospitals in the Social
Security Mexican Institute. METHODS: A decision tree model
was developed using a Bayesian approach. The model simulated
treatment of a hypothetical cohort of 1000 patients diagnosed
with osteoarthritis during a time horizon of 6 months. Patients
could initiate treatment with celecoxib, NSAIDs (diclofenac,
naproxen) and acetaminophen. Conditional probabilities of the
